Pfizer Reports Encouraging Overall Survival Results in Phase 3 Study of ADCETRIS® Treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma

Pfizer Inc. (NYSE: PFE) has disclosed promising findings from a Phase 3 clinical trial investigating the efficacy of the antibody-drug conjugate ADCETRIS® (brentuximab vedotin) in conjunction with lenalidomide and rituximab for treating patients afflicted with relapsed/refractory diffuse large B-cell lymphoma…

Read MorePfizer Reports Encouraging Overall Survival Results in Phase 3 Study of ADCETRIS® Treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma

Merck Unveils Clinical Trial Strategy for New HPV Vaccine and GARDASIL®9 Single-Dose Regimen

Merck (NYSE: MRK), also known as MSD outside the United States and Canada, made a significant announcement today at the EUROGIN 2024 HPV Congress. The company revealed its intentions to commence clinical development of a groundbreaking investigational multi-valent HPV vaccine…

Read MoreMerck Unveils Clinical Trial Strategy for New HPV Vaccine and GARDASIL®9 Single-Dose Regimen

Hansoh Pharma Enhances Collaboration with Biotheus to Advance Development of EGFR/cMET Bispecific Antibody-Drug Conjugates

Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma, 03692.HK), a leading innovative pharmaceutical company in China, and Biotheus Inc. (Biotheus), a clinical-stage biotech company specializing in biologics for oncology and inflammatory diseases, have jointly announced an expansion of their strategic partnership.…

Read MoreHansoh Pharma Enhances Collaboration with Biotheus to Advance Development of EGFR/cMET Bispecific Antibody-Drug Conjugates

Update Consultation by WHO Experts: Revising Toxic Equivalency Factors for Dioxin-like Compounds and Selected Polychlorinated Biphenyls

In Lisbon, Portugal, the World Health Organization (WHO) recently hosted an expert panel to reassess the Toxic Equivalency Factors (TEFs) for chlorinated dioxin-like compounds, initially established in 2005. Background: Since the 1990s, WHO has consistently organized expert consultations aimed at…

Read MoreUpdate Consultation by WHO Experts: Revising Toxic Equivalency Factors for Dioxin-like Compounds and Selected Polychlorinated Biphenyls

Neurological Conditions Impact Over 1 in 3 Individuals, Ranking as the Primary Cause of Global Illness and Disability

A recent comprehensive study, published in The Lancet Neurology, has revealed staggering figures regarding neurological conditions worldwide. In 2021, over 3 billion individuals were found to be living with such conditions, marking them as the foremost cause of global illness…

Read MoreNeurological Conditions Impact Over 1 in 3 Individuals, Ranking as the Primary Cause of Global Illness and Disability

WHO and UNICEF Introduce Complimentary Online Course on Children’s Environmental Health

Amidst the escalating challenges posed by environmental pollution and climate change, the World Health Organization (WHO) and the United Nations Children’s Fund (UNICEF) have joined forces to launch a new online course, free of charge, aimed at empowering healthcare providers…

Read MoreWHO and UNICEF Introduce Complimentary Online Course on Children’s Environmental Health

Gender Disparities Unveiled: The Core of the Worldwide Health and Care Work Crisis, According to WHO Report

The latest publication from the World Health Organization (WHO), titled “Equity in Health and Care: Gender Dynamics in Undervalued Health and Care Labor,” sheds light on how gender disparities within health and care sectors detrimentally affect women, health infrastructures, and…

Read MoreGender Disparities Unveiled: The Core of the Worldwide Health and Care Work Crisis, According to WHO Report

Ionis Reports Encouraging Findings from Phase 2 Trial of ION224, Showing Clinical Effectiveness in NASH/MASH Treatment

Ionis has unveiled encouraging outcomes from its Phase 2 investigation of ION224, a DGAT2 antisense inhibitor aimed at addressing metabolic dysfunction-associated steatohepatitis (MASH), previously termed nonalcoholic steatohepatitis (NASH). The study, encompassing 160 patients over 51 weeks, successfully met its primary…

Read MoreIonis Reports Encouraging Findings from Phase 2 Trial of ION224, Showing Clinical Effectiveness in NASH/MASH Treatment

The Chemical Quality Control Laboratory: Guardian of Standards in the Pharmaceutical Plant

The Role of Quality Control at Orion Pharmaceuticals Maija Blomquist, the Quality Control Manager for Materials, Gels & Ointments, underscores the pivotal role of quality control in maintaining Orion’s product standards. Acting as sentinels throughout the production cycle, her team…

Read MoreThe Chemical Quality Control Laboratory: Guardian of Standards in the Pharmaceutical Plant